Related Experiment Video

Updated: Aug 3, 2025

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

1.7K

Ceftobiprole medocaril for the treatment of pneumonia

Wan-Hsuan Hsu1, Chi-Kuei Hsu2,3, Chih-Cheng Lai4,5

  • 1Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.

Expert Review of Anti-Infective Therapy
|April 12, 2023
PubMed
Abstract

Insights

Ceftobiprole, a fifth-generation cephalosporin, effectively treats pneumonia, including infections from multidrug-resistant organisms (MDROs) like MRSA. Its properties allow excellent lung penetration and broad-spectrum activity, making it a valuable option for empirical pneumonia therapy.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Pulmonology

Background:

  • Pneumonia treatment faces challenges from multidrug-resistant organisms (MDROs).
  • Ceftobiprole, a fifth-generation cephalosporin, offers broad-spectrum activity against common pneumonia pathogens.
  • It is effective against challenging MDROs, including methicillin-resistant Staphylococcus aureus (MRSA) and penicillin-resistant Streptococcus pneumoniae (PRSP).

Approach:

  • This review discusses the role of ceftobiprole in pneumonia treatment.
  • Ceftobiprole inhibits bacterial transpeptidases, with high affinity for penicillin-binding proteins (PBPs) 2a, PBP2x, and PBP3.
  • Minimal plasma protein binding facilitates high lung tissue and epithelial fluid concentrations.

Key Points:

  • Ceftobiprole demonstrates potent in vitro activity against S. aureus, S. pneumoniae, H. influenzae, M. catarrhalis, and Enterobacterales.
  • It shows particular efficacy against MRSA and Pseudomonas aeruginosa.
  • Randomized controlled trials confirm the clinical efficacy and safety of ceftobiprole in adults and children.

Conclusions:

  • Ceftobiprole is a potential alternative for empirical pneumonia treatment in patients at high risk for MDROs.
  • Its favorable pharmacokinetic and pharmacodynamic properties support its use.
  • Ceftobiprole has proven efficacy in community-acquired and hospital-acquired pneumonia, excluding ventilator-associated pneumonia.
Keywords:
CeftobiprolePseudomonas aeruginosacommunity-acquired pneumoniahospital-acquired pneumoniamethicillin-resistantStaphylococcus aureus

More Related Videos

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE03:22

Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE

Published on: March 1, 2024

489
Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia13:27

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia

Published on: May 6, 2014

48.1K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
407
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.3K
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
185
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
289
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
379
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
258